Wegovy Pill (oral semaglutide 25 mg)vsLifeMD Wegovy Pill Telehealth Program

Semaglutide is a GLP-1 receptor agonist. It mimics the gut hormone GLP-1 to boost glucose-dependent insulin release, slow how fast the stomach empties, and signal fullness in the brain, which together reduce appetite and calorie intake. The oral formulation uses an absorption enhancer (SNAC) to get the peptide across the stomach lining, which is why empty-stomach dosing matters.

The therapeutic agent is oral semaglutide (Wegovy pill), a GLP-1 receptor agonist that curbs appetite, slows gastric emptying, and improves blood-sugar handling. LifeMD's role is the service layer: a licensed clinician evaluates eligibility, prescribes the branded drug, and provides ongoing monitoring, dose adjustments, and fulfillment.

In the phase 3 OASIS 4 trial (NEJM, 2025; n=307 adults with overweight/obesity, without diabetes), oral semaglutide 25 mg produced an estimated mean weight change of -13.6% at week 64 versus -2.2% for placebo, with about 30% of the drug group losing at least 20% of body weight. Novo reports up to ~16.6% mean loss with full adherence, on par with injectable Wegovy 2.4 mg.

Because LifeMD dispenses the same FDA-approved oral semaglutide 25 mg, the expected efficacy mirrors the OASIS 4 trial (NEJM, 2025): roughly 13.6% mean weight loss at 64 weeks (up to ~16.6% with full adherence). The added telehealth coaching and check-ins are designed to support adherence, which is the main driver of real-world results.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation, typically worst during dose escalation and easing over time. Rare but serious risks include pancreatitis and gallbladder problems; it carries a boxed warning for thyroid C-cell tumors based on animal data. Discuss your history with a licensed provider.

Side effects come from the medication itself, primarily GI effects like nausea, diarrhea, vomiting, and constipation, usually most pronounced during dose escalation. Serious but rare risks include pancreatitis; the drug carries a boxed warning for thyroid C-cell tumors. LifeMD clinicians monitor and adjust dosing to manage tolerability.

As of May 2026, self-pay pricing starts around $149/month for the 1.5 mg starter and 4 mg doses, with 4 mg rising to $199/month after April 15, 2026 and higher maintenance doses around $299/month. Commercially insured patients with coverage may pay as little as $25/month with the savings offer. Confirm current pricing at NovoCare or your pharmacy.

As of September 2026, LifeMD charges a $149 program and provider fee (currently discounted to $75) on top of the Wegovy pill, which starts at $149/month without insurance for the 1.5 mg dose; higher doses cost $199–$299/month at NovoCare's self-pay prices. Verify current pricing with LifeMD.

Intended for adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related condition, used with diet and exercise. Not for people with a personal or family history of medullary thyroid carcinoma or MEN2, and prescribers screen for pancreatitis history and other GLP-1 contraindications.

Adults with obesity or overweight with a weight-related condition who qualify after a telehealth evaluation in any of the 50 states. The same contraindications as Wegovy apply, including a personal or family history of medullary thyroid carcinoma or MEN2. A clinician makes the final prescribing decision.